This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
09/16/2026
2 min read
News
